Truvestments Capital’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$41.4K Hold
220
0.01% 525
2025
Q4
$41.6K Hold
220
0.01% 483
2025
Q3
$36.5K Sell
220
-30
-12% -$4.89K 0.01% 490
2025
Q2
$38.3K Hold
250
0.01% 436
2025
Q1
$39.3K Hold
250
0.01% 442
2024
Q4
$39.2K Hold
250
0.01% 409
2024
Q3
$44.3K Buy
+250
New +$44.4K 0.01% 372
2024
Q2
Sell
-250
Closed -$41.6K 269
2024
Q1
$41.6K Hold
250
0.02% 369
2023
Q4
$41.3K Hold
250
0.02% 344
2023
Q3
$38.9K Hold
250
0.02% 307
2023
Q2
$39K Hold
250
0.02% 313
2023
Q1
$40.5K Hold
250
0.02% 307
2022
Q4
$39.9K Hold
250
0.02% 320
2022
Q3
$35K Hold
250
0.02% 288
2022
Q2
$36K Buy
+250
New +$37.2K 0.02% 288
2022
Q1
Sell
-250
Closed -$47K 217
2021
Q4
$47K Hold
250
0.02% 274
2021
Q3
$51K Hold
250
0.03% 249
2021
Q2
$50K Sell
250
-25
-9% -$4.65K 0.03% 249
2021
Q1
$48K Hold
275
0.03% 283
2020
Q4
$46K Buy
+275
New +$45.3K 0.03% 271
2020
Q3
Sell
-275
Closed -$44K 345
2020
Q2
$44K Buy
+275
New +$41.8K 0.04% 219
2019
Q4
Sell
-275
Closed -$32K 182
2019
Q3
$32K Hold
275
0.02% 323
2019
Q2
$35K Buy
+275
New +$33.9K 0.02% 331

Other funds holding BBH

Truvestments Capital's BBH Position: Q1 2026 in Review

Truvestments Capital held its VanEck Biotech ETF (BBH) position steady in Q1 2026 at 220 shares worth $41.4K. The position accounts for 0.01% of the portfolio, ranked #525.

Truvestments Capital first reported a position in BBH in Q2 2019 and has held it in 23 quarters since. The position peaked at $51K in Q3 2021. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • Truvestments Capital held 220 shares of VanEck Biotech ETF worth $41.4K as of Q1 2026.
  • Truvestments Capital left its VanEck Biotech ETF share count unchanged in Q1 2026.
  • VanEck Biotech ETF made up 0.01% of Truvestments Capital's portfolio in Q1 2026, its #525 holding.
  • Truvestments Capital first reported a position in VanEck Biotech ETF in Q2 2019 and has held it in 23 quarters since.
  • Truvestments Capital's VanEck Biotech ETF position peaked at $51K in Q3 2021.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.